IDEXX Laboratories tops revenue forecasts, shares edge lower on outlook
February 2, 2026 8:47 AM
IH Market News
IDEXX Laboratories (NASDAQ:IDXX) posted a solid set of fourth-quarter results on Monday, with revenue rising 14% to $1.09 billion, beating analyst estimates of $1.07 billion, helped by strong momentum in its companion animal diagnostics operations.
Despite the revenue beat, IDEXX shares slipped 0.37% in premarket trading after the release.
The company’s guidance for 2026 was broadly in line with market expectations. IDEXX forecast full-year revenue of between $4.63 billion and $4.72 billion, with earnings per share projected in the range of $14.29 to $14.80.
For the quarter, adjusted earnings per share came in at $2.92, just below the consensus estimate of $2.93. Revenue growth was underpinned by a 12% increase in recurring revenue from CAG Diagnostics, which reached $849.7 million. IDEXX also reported a record number of quarterly instrument placements, including more than 1,900 IDEXX inVue Dx systems.
“2025 was a pivotal year for the Company, marked by the successful launch of IDEXX Cancer Dx for canine lymphoma and meaningful adoption of IDEXX inVue Dx well ahead of our initial goals,” said Jay Mazelsky, president and chief executive officer.
Profitability improved during the quarter, with operating margin expanding by 150 basis points year on year to 28.9%, while adjusted operating margin rose by 120 basis points. The CAG segment, which supports veterinary clinics, recorded a 15% increase in revenue to $998.5 million, with international markets growing 17%.
IDEXX’s Water segment also delivered a strong performance, as revenue climbed 12% to $50.5 million. The company’s global installed base of premium instruments grew 12% from a year earlier, helping drive a 17% increase in consumables revenue.
Looking ahead to 2026, IDEXX expects organic revenue growth of 7.0% to 9.0%, led by organic growth of 8.0% to 10.0% in CAG Diagnostics recurring revenue. The company also anticipates operating margin expansion of between 40 and 90 basis points.
IDEXX Laboratories stock price
Original: IDEXX Laboratories tops revenue forecasts, shares edge lower on outlook
Market Data 
Markets 
AI
